Anavex Life Sciences Corp. AVXL 深 沪
等待开盘 03-26 09:30:00 美东时间
2.745
-1.445
-34.49%
华盛通- 最 高3.115
- 今 开2.95
- 成交量 1109.43万股
- 最 低 2.6916
- 昨 收 4.19
- 总市值 2.54亿
- 52周最高 13.99
- 市盈率 静 --
- 换手率 11.97%
- 52周最低 2.6916
- 委 比 -53.53%
- 总股本 9267.18万
- 历史最高 31.50
- 量 比 8.61
- 振 幅 10.11%
- 历史最低 0.60
- 每 手 1
- 风险率 2.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Anavex drops after pulling EU marketing application for Alzheimer’s therapy
Anavex Life Sciences (AVXL) lost ~18% in the premarket on Wednesday after the company announced that it withdrew the marketing authorization application for its Alzheimer’s candidate, blarcamesine, in...
03-25 19:57
Anavex Withdraws EU Filing For Alzheimer's Treatment After Regulator Feedback
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,
03-25 19:34
Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion
Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion Anavex Life Sciences withdrew its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzhei
03-25 19:29
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences withdrew its EU marketing authorization application for blarcamesine as an add-on therapy for early Alzheimer's disease due to feedback from the EMA’s CHMP indicating it couldn’t issue a positive opinion at this time. The company remains committed to advancing blarcamesine’s clinical development to address the significant unmet medical needs of early Alzheimer’s patients, supported by feedback from the CHMP and advocacy group...
03-25 11:30
Anavex reports blarcamesine rescued motor function in new Parkinson’s disease model after 6 weeks of treatment
Anavex reports blarcamesine rescued motor function in new Parkinson’s disease model after 6 weeks of treatment Anavex reported preclinical data showing blarcamesine completely rescued impaired motor function in a Parkinson’s disease model combining alpha-synuclein pathology and noradrenergic degener
03-17 19:35
Anavex Tests Parkinson's Drug That May Help Regrow Brain Cells
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,
03-17 19:32
Anavex reports blarcamesine motor function rescue in new Parkinson’s disease model at AD/PD 2026
Anavex reports blarcamesine motor function rescue in new Parkinson’s disease model at AD/PD 2026 Anavex reported new preclinical data on blarcamesine in a Parkinson’s disease model combining alpha-synuclein pathology and noradrenergic degeneration. The results were presented at the AD/PD 2026 Confer
03-17 19:31
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
New data shows that blarcamesine significantly improved motor function and promoted dopaminergic nerve fiber regrowth in a novel Parkinson's model combining alpha-synuclein pathology and noradrenergic degeneration. Results, presented at the AD/PD 2026 Conference, indicate potential disease-modifying effects of blarcamesine in reversing Parkinson's progression. Researchers are encouraged by these findings, which support further clinical developmen...
03-17 11:30
What's Going On With Anavex Life Sciences Stock On Wednesday?
Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.
03-05 02:32
